Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Nicotinamide Mononucleotide (NMN) Market will Turn over USD 251.2 to Revenue to Cross USD 953 million in 2022 to 2028 Research by Business Opportunities, Top Companies, opportunities planning, Market-specific challenges

Published

on

PUNE, Aug. 19, 2022 (GLOBE NEWSWIRE) — Global “Nicotinamide Mononucleotide (NMN) Market” research report focus on overall information that can help to take decisions on current market situation. global economy mends, the 2021 growth of Nicotinamide Mononucleotide (NMN) will have significant change from previous year. According to our researcher latest study, the global Nicotinamide Mononucleotide (NMN) market size is USD million in 2022 from USD 251.2 million in 2021, with a change of % between 2021 and 2022. The global Nicotinamide Mononucleotide (NMN) market size will reach USD 953 million in 2028, growing at a CAGR of 21.0% over the analysis period 2022-2028.

Nicotinamide Mononucleotide (NMN) Market Report Contains: –

  • Complete overview of the global Nicotinamide Mononucleotide (NMN) Market
  • Top Country data and analysis for United States, Canada, Mexico, Germany, France, United Kingdom, Russia, Italy, China, Japan, Korea, India, Southeast Asia, Australia, Brazil and Saudi Arabia, etc. It also throws light on the progress of key regional Nicotinamide Mononucleotide (NMN) markets such as North America, Europe, Asia-Pacific, South America and Middle East and Africa
  • Description and analysis of Nicotinamide Mononucleotide (NMN) market potential by type, Deep Dive, disruption, application capacity, end use industry
  • impact evaluation of most important drivers and restraints, and dynamics of the global Nicotinamide Mononucleotide (NMN) market and current trends in the enterprise
  • Detailed profiles of the Top major players in the industry, including. GeneHarbor,Herbalmax,Genex Formulas,Shinkowa Pharmaceutical,Maac10 Formulas,EffePharm,Bontac,CELFULL,Kingdomway

Get a Sample Copy of the Report at – https://proficientmarketinsights.com/enquiry/request-sample/21360948?utm_source=ng

Nicotinamide Mononucleotide (NMN) Market Segmentation: –

“Nicotinamide Mononucleotide (NMN) Market Size 2022” research report focus on overall information that can help to take decisions on current market situation. This report provides information about Size, Types, Application, Production, Revenue, Growth Rate, Gross margin, opportunities with future risk analysis. The report also describes top company profiles that present in market with trends worldwide. This article contains financial changes during years with Impact of COVID-19 on Nicotinamide Mononucleotide (NMN) market.

The United States Nicotinamide Mononucleotide (NMN) market is expected at value of US$ million in 2021 and grow at approximately % CAGR during forecast period 2022-2028. China constitutes a % market for the global Nicotinamide Mononucleotide (NMN) market, reaching US$ million by the year 2028. As for the Europe Nicotinamide Mononucleotide (NMN) landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 6-year period.

Global main Nicotinamide Mononucleotide (NMN) players cover GeneHarbor, Herbalmax, Genex Formulas, and Shinkowa Pharmaceutical, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

This report presents a comprehensive overview, market shares, and growth opportunities of Nicotinamide Mononucleotide (NMN) market by product type, application, key manufacturers and key regions and countries.

Nicotinamide Mononucleotide (NMN) Market segments help decision-makers direct the product, sales, and marketing strategies, and can power your product development cycles by informing how you make product offerings for different segments.

Segmentation by purity: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6

  • Content Greater than or Equal to 98%
  • Content Less than 98%

Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.

  • Health Care Products
  • Cosmetics
  • Others

Market segment by Region/Country including: –

  • North America (United States, Canada, and Mexico)
  • Europe (Germany, UK, France, Italy, Russia and Spain, etc.)
  • Asia-Pacific (China, Japan, Korea, India, Australia, Southeast Asia, etc.)
  • South America (Brazil, Argentina, Colombia, etc.)
  • Middle East & Africa (South Africa, UAE, Saudi Arabia, etc.)

Inquire or Share Your Questions If Any Before the Purchasing This Report – https://proficientmarketinsights.com/enquiry/pre-order-enquiry/21360948?utm_source=ng

Key Players in the Nicotinamide Mononucleotide (NMN) Market: –

  • GeneHarbor
  • Herbalmax
  • Genex Formulas
  • Shinkowa Pharmaceutical
  • Maac10 Formulas
  • EffePharm
  • Bontac
  • CELFULL
  • Kingdomway

Get a Sample Copy of the Report at – https://proficientmarketinsights.com/enquiry/request-sample/21360948?utm_source=ng

Key Benefits of Nicotinamide Mononucleotide (NMN) Market Research Report:

  • Types, applications, regions, and key players covered in the study
  • Industry drivers, restraints, and opportunities covered in the study
  • Recent industry trends and developments
  • Competitive landscape & strategies of key players
  • Historical, current, and projected market size, in terms of value
  • In-depth analysis of the Artificial Intelligence AI Chips Market
  • Sales, price, revenue, market share, and growth rate are covered in the report sales channels, distributors, traders, dealers, etc. are covered in the report

Detailed TOC of Global Nicotinamide Mononucleotide (NMN) Market Growth 2022-2028

1 Scope of the Report

    1.1 Market Introduction

    1.2 Years Considered

    1.3 Research Objectives

    1.4 Market Research Methodology

    1.5 Research Process and Data Source

    1.6 Economic Indicators

    1.7 Currency Considered

2 Executive Summary

    2.1 World Market Overview

        2.1.1 Global Nicotinamide Mononucleotide (NMN) Annual Sales 2017-2028

        2.1.2 World Current & Future Analysis for Nicotinamide Mononucleotide (NMN) by Geographic Region, 2017, 2022 & 2028

        2.1.3 World Current & Future Analysis for Nicotinamide Mononucleotide (NMN) by Country/Region, 2017, 2022 & 2028

    2.2 Nicotinamide Mononucleotide (NMN) Segment by Purity

        2.2.1 Content Greater than or Equal to 98%

        2.2.2 Content Less than 98%

    2.3 Nicotinamide Mononucleotide (NMN) Sales by Purity

        2.3.1 Global Nicotinamide Mononucleotide (NMN) Sales Market Share by Purity (2017-2022)

        2.3.2 Global Nicotinamide Mononucleotide (NMN) Revenue and Market Share by Purity (2017-2022)

        2.3.3 Global Nicotinamide Mononucleotide (NMN) Sale Price by Purity (2017-2022)

    2.4 Nicotinamide Mononucleotide (NMN) Segment by Application

        2.4.1 Health Care Products

        2.4.2 Cosmetics

        2.4.3 Others

    2.5 Nicotinamide Mononucleotide (NMN) Sales by Application

        2.5.1 Global Nicotinamide Mononucleotide (NMN) Sale Market Share by Application (2017-2022)

        2.5.2 Global Nicotinamide Mononucleotide (NMN) Revenue and Market Share by Application (2017-2022)

        2.5.3 Global Nicotinamide Mononucleotide (NMN) Sale Price by Application (2017-2022)

3 Global Nicotinamide Mononucleotide (NMN) by Company

    3.1 Global Nicotinamide Mononucleotide (NMN) Breakdown Data by Company

        3.1.1 Global Nicotinamide Mononucleotide (NMN) Annual Sales by Company (2020-2022)

        3.1.2 Global Nicotinamide Mononucleotide (NMN) Sales Market Share by Company (2020-2022)

    3.2 Global Nicotinamide Mononucleotide (NMN) Annual Revenue by Company (2020-2022)

        3.2.1 Global Nicotinamide Mononucleotide (NMN) Revenue by Company (2020-2022)

        3.2.2 Global Nicotinamide Mononucleotide (NMN) Revenue Market Share by Company (2020-2022)

    3.3 Global Nicotinamide Mononucleotide (NMN) Sale Price by Company

    3.4 Key Manufacturers Nicotinamide Mononucleotide (NMN) Producing Area Distribution, Sales Area, Product Type

        3.4.1 Key Manufacturers Nicotinamide Mononucleotide (NMN) Product Location Distribution

        3.4.2 Players Nicotinamide Mononucleotide (NMN) Products Offered

Explore Full Report With Detailed TOC Here: https://proficientmarketinsights.com/TOC/21360948?utm_source=ng#TOC

1.To study and analyze the global Nicotinamide Mononucleotide (NMN) consumption (value) by key regions/countries, product type and application

2.To understand the structure of Nicotinamide Mononucleotide (NMN) market by identifying its various sub segments.

3.Focuses on the key global Nicotinamide Mononucleotide (NMN) manufacturers, to define, describe and analyze the value, market share, market competition landscape, Porter’s five forces analysis, SWOT analysis and development plans in next few years.

4.To analyze the Nicotinamide Mononucleotide (NMN) with respect to individual growth trends, future prospects, and their contribution to the total market.

5.To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

6.To project the consumption of Nicotinamide Mononucleotide (NMN) submarkets, with respect to key regions (along with their respective key countries).

7.To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

8.To strategically profile the key players and comprehensively analyze their growth strategies.

Key Reasons to Purchase

To gain insightful analyses of the market and have comprehensive understanding of the global Nicotinamide Mononucleotide (NMN) market and its commercial landscape.

Assess the production processes, major issues, and solutions to mitigate the development risk.

To understand the most affecting driving and restraining forces in the Nicotinamide Mononucleotide (NMN) market and its impact in the global market.

Learn about the Nicotinamide Mononucleotide (NMN) market strategies that are being adopted by leading respective organizations.

To understand the future outlook and prospects for the Nicotinamide Mononucleotide (NMN) market.

Besides the standard structure reports, we also provide custom research according to specific requirements

Purchase this Report (Price 3660 USD for a Single-User License) – https://proficientmarketinsights.com/purchase/21360948?utm_source=ng

About Proficient market insights:

Proficient market insights is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in-depth market research. We are one of the top report resellers in the market, dedicated to bringing you an ingenious concoction of data parameters.


GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Enghouse Video Partners With SONIFI Health To Deliver Advanced Telehealth Solutions In Hospital Rooms

Published

on

enghouse-video-partners-with-sonifi-health-to-deliver-advanced-telehealth-solutions-in-hospital-rooms

MARKHAM, ON, April 25, 2024 /PRNewswire/ — Enghouse Video, a global leader in cutting-edge video technology solutions, today announced its partnership with SONIFI Health, enhancing virtual care in hospital settings.

SONIFI Health is a leading U.S. healthcare technology company based in Sioux Falls, South Dakota. The new partnership leverages and integrates Enghouse Video room systems technology to support SONIFI Health’s commitment to expanding telehealth applications and system optimizations in hospital settings.
Enghouse’s VidyoRooms solution, a sophisticated video conferencing technology that combines both software and hardware solutions, has been fully integrated into SONIFI Health’s interactive TV systems. This integration provides up to 4K high-quality video conferencing, multi-party sessions and robust security features that ensure full compliance with healthcare regulations.
Enghouse Video offers an immersive telehealth platform to support collaborative interdisciplinary care, improved patient outcomes and cost savings. The platform is flexible and simple, delivering the reliability, interoperability, and scalability needed for today’s healthcare environment. A key strength of the partnership is its offering of back-end integrations like patient portals, medical devices, EMR, tele-sitting, remote patient observation and consultation.
“Hospitals can choose the telehealth partner that’s right for them, and we incorporate that solution with interactive TV,” said Brian Nido, SONIFI Health’s Vice President of Customer Success. “Using the hardware and systems they already have in patient rooms helps hospitals reduce costs and maximize the value of their existing investments, while benefiting both clinicians and patients.”
SONIFI Health and Enghouse Video continue to collaborate closely to further refine and enhance the telehealth solutions provided to healthcare facilities. This partnership reflects a shared commitment to leveraging technology to create smarter hospital rooms and improve patient care across the healthcare spectrum.
About Enghouse VideoEnghouse Video, part of the Enghouse Interactive division, is a subsidiary of Enghouse Systems Limited, a vertically focused software and services company traded on the Toronto Stock Exchange (TSX: ENGH). Through highly secure, scalable and flexible Cloud-based or On Prem services, we deliver one of the world’s highest quality and most innovative video platform to video-enable any application or idea. From advanced video conferencing and collaboration tools to state-of-art enterprise video management, Enghouse Video is a unique player in multiple markets, including telehealth. Learn more at www.enghousevideo.com, read our blog, or follow us on Twitter at @EnghouseVideo, on LinkedIn, and on Facebook.
About SONIFI HealthSONIFI Health provides market-leading interactive patient engagement technology proven to improve patient outcomes and staff productivity. The EHR-integrated platform is designed to enhance patient and family experiences while increasing staff satisfaction and organizations’ operational efficiencies. As part of SONIFI Solutions, Inc., the company annually supports more than 300 million end user experiences. Learn more at sonifihealth.com.
Enghouse Video Contact: Sylvain Awad, Director, Demand Generation, Enghouse Video, part of Enghouse Interactive Division, [email protected]

View original content:https://www.prnewswire.co.uk/news-releases/enghouse-video-partners-with-sonifi-health-to-deliver-advanced-telehealth-solutions-in-hospital-rooms-302126882.html

Continue Reading

Artificial Intelligence

Global Insurance Provider Selects 3CLogic to Streamline AI and Contact Center Capabilities with ServiceNow

Published

on

global-insurance-provider-selects-3clogic-to-streamline-ai-and-contact-center-capabilities-with-servicenow

Multinational Insurance Broker to deploy 3CLogic’s solution with ServiceNow’s Financial Service Operations (FSO) platform to streamline customer experiences.
ROCKVILLE, Md., April 25, 2024 /PRNewswire/ — 3CLogic, the leading Conversational AI and Contact Center solution for ServiceNow®, today announced its selection by a global insurance provider to replace its existing contact center infrastructure as part of a larger CX transformation effort. The strategic decision is designed to complement the organization’s use of ServiviceNow’s Financial Services Operations (FSO) offering leveraged across a number of its existing product lines including Customer Warranty Claims, Roadside Assistance, and Home Warranties.

Serving millions of customers worldwide with innovative insurance and protective products, the organization required a solution that would enhance its recent investment in the ServiceNow platform as it works to transform its end-to-end customer service operations. The deployment will incorporate several of 3CLogic’s AI-powered capabilities purpose-built for ServiceNow, including Conversational AI, Speech Analytics, and AI Performance & Coaching, along with integrated call transcriptions, convenient 2-way SMS, and ServiceNow-centralized contact center reporting.
“We continue to see enterprises eager to complement their existing investment in digital platforms, such as ServiceNow, with contact center features purpose-built to extend the workflows and features they already have and use,” explains Matt Durkin, VP of Global Sales at 3CLogic. “It’s no secret that organizations are already juggling too many systems, often with overlapping capabilities, which impacts ROI and operational efficiency. We’re proud to offer an alternative approach that helps simplify the technology stack while optimizing the overall operational costs and outcomes.”
Recently named to Constellation Research’s 2024 Shortlist for Digital Customer Service and Support, 3CLogic has seen global adoption of its solution by leading enterprises in healthcare, manufacturing, travel, retail, higher education, finance, non-profits, and Managed Service Providers across five continents. As a ServiceNow-certified Technology and Build partner with offerings available for ServiceNow’s IT Service Management, Customer Workflows, HR Service Delivery, and Source-to-Pay solutions, the company will be unveiling its latest set of capabilities at ServiceNow’s annual Knowledge 2024 event this May in Las Vegas.
For more information, please contact [email protected].
About 3CLogic3CLogic transforms customer and employee experiences with its leading Cloud Contact Center and AI solutions purpose-built to enhance today’s leading CRM and Customer Service Management platforms. Globally available and leveraged by the world’s leading brands, its offerings empower enterprise organizations with innovative features such as intelligent self-service, generative and Conversational AI, agent automation & coaching, and AI-powered sentiment analytics – all designed to lower operational costs, maximize ROI, and optimize each interaction across IT Service Desks, Customer Support, Sales or HR Services teams. For more information, please visit www.3clogic.com.
Logo – https://mma.prnewswire.com/media/2318845/3CLogic_logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/global-insurance-provider-selects-3clogic-to-streamline-ai-and-contact-center-capabilities-with-servicenow-302127739.html

Continue Reading

Artificial Intelligence

ScreenPoint Medical Leadership Transition: Pieter Kroese Confirmed as CEO

Published

on

screenpoint-medical-leadership-transition:-pieter-kroese-confirmed-as-ceo

Leading Breast AI Company, creator of industry-leading Transpara®, promotes from within for new CEO
NIJMEGEN, Netherlands, April 25, 2024 /PRNewswire/ — ScreenPoint Medical, today announced a significant transition in its leadership as Mark Koeniguer, the current CEO, steps down from his position. Mark served as CEO since 2022 and was instrumental in ScreenPoint’s commercial growth and success over the past 2 years.

 
 
The company’s Board of Directors has appointed Pieter Kroese as the new Chief Executive Officer effective April 25, 2024. Pieter takes the role after serving as COO of ScreenPoint for over five years. During that time, he has managed the transition of the company from an early startup to a thriving enterprise with hundreds of customers using ScreenPoint’s flagship Transpara software to support millions of scans a year.
“I am thrilled to lead ScreenPoint into its next phase of growth and innovation,” said Mr. Kroese. “I am deeply committed to building upon the strong foundation we have and continuing to work closely with our talented team to drive continued success. We are already expanding screening capacity and capability through proven reader support – we look forward to increasing our ability to support providers and women moving forward.”
Sir Michael Brady, Chairman of the Board at ScreenPoint Medical and a co-founder of the company, expressed enthusiasm about Pieter’s appointment, stating, “Pieter’s remarkable leadership qualities, coupled with his depth of knowledge of our product and industry, make him the perfect choice to lead ScreenPoint into the future. His strategic mindset and commitment to excellence align perfectly with our company mission of early breast cancer detection. Pieter has been an integral part of our growth to date and will provide seamless leadership through this transition into our next chapter for our customers, partners, and team.”
Author of “No Longer Radical” and over a hundred peer-reviewed publications on breast imaging, Dr. Rachel Brem is a Transpara user and ScreenPoint Board Member. Dr. Brem welcomed Mr. Kroese with the following: “Pieter has been an integral part of the ScreenPoint team for years. I am confident that his leadership will continue to deliver product excellence: earlier detection with outstanding reading workflow and improved patient outcomes. We continue to see these results from clinical sites all over the world, including many here in the United States. No other Breast AI solution has demonstrated the same results as Transpara, and I am confident that the team will continue to push on these frontiers under Pieter’s leadership.” 
The entire team at ScreenPoint extends its gratitude to Mark Koeniguer and wishes him every success in the future, while warmly welcoming Pieter Kroese into his new role as CEO.
About ScreenPoint Medical
ScreenPoint Medical translates cutting edge machine learning research into technology accessible by radiologists to improve screening workflow, decision confidence and breast cancer risk assessment. Transpara is trusted by radiologists globally because it has been developed by experts in machine learning and image analysis and updated with user feedback from world-renowned breast imagers.
See all the proof at: https://screenpoint-medical.com/evidence.
Photo: https://mma.prnewswire.com/media/2397831/Pieter_Kroese_CEO_ScreenPoint_Medical.jpgLogo: https://mma.prnewswire.com/media/1582198/ScreenPoint_Medical_Logo.jpg
 
 

View original content:https://www.prnewswire.co.uk/news-releases/screenpoint-medical-leadership-transition-pieter-kroese-confirmed-as-ceo-302127719.html

Continue Reading

Trending